SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad

Area of Science:

• Cardiovascular Medicine
• Virology
• Molecular Biology

Background:

• Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, often leads to severe respiratory and cardiovascular complications.
• Patients with pre-existing cardiovascular diseases (CVD) face increased severity and mortality risk from COVID-19 due to heightened inflammatory responses.

Purpose of the Study:

• To elucidate the intricate mechanisms connecting COVID-19 and CVD.
• To explore the role of noncoding RNAs (ncRNAs) in SARS-CoV-2 infection and its cardiovascular sequelae.
• To identify ncRNAs as potential targets for novel pharmacological interventions.

Main Methods:

• Literature review of existing studies on COVID-19, CVD, and ncRNAs.
• Analysis of molecular interactions between SARS-CoV-2 and host cardiovascular systems.
• Discussion of ncRNA-mediated gene regulation in the context of viral infection and cardiovascular damage.

Main Results:

• Established clinical associations between COVID-19 and CVD severity.
• Identified ncRNAs as key regulators of gene expression during SARS-CoV-2 infection.
• Highlighted the potential of ncRNAs in modulating inflammatory responses and cardiovascular outcomes.

Conclusions:

• Noncoding RNAs represent a promising therapeutic avenue for managing COVID-19, particularly in patients with cardiovascular comorbidities.
• Further research into ncRNA mechanisms can lead to the development of targeted pharmacological treatments for COVID-19 and its cardiovascular complications.